NewConnect-listed Genomtec says its genetic tests detect Omicron variant

Genomtec S.A. “GMT”, a MedTech company listed on NewConnect, specializing in the development of advanced technology in the field of genetic diagnosis at the point of care (POCT), conducted an analysis of its rapid genetic tests, which confirmed their effectiveness in detecting all known variants of the SARS virus – CoV-2 in this recently discovered Omicron variant.

Due to growing concerns about the ability of IVD tests to recognize newly emerging SARS-CoV-2 variants, Genomtec has performed an in-silico bioinformatics analysis and laboratory analysis for the Genomtec® SARS-CoV-2 EvaGreen® RT-LAMP CE- diagnostic kits. IVD Duo Kit (RT-LAMP Duo) and Genomtec® SARS-CoV-2 EvaGreen® Direct-RT-LAMP CE-IVD Kit (Direct).

The results of the analyzes fully confirmed the effectiveness of the RT-LAMP Duo and Direct kits in recognizing the SARS-CoV-2 variants identified so far, including the newly discovered Omicron variant.

“The ability to recognize multiple SARS-CoV-2 variants by Genomtec’s RT-LAMP Duo and Direct kits is important for public health, when effective testing capable of detecting particularly dangerous SARS-CoV-2 virus strains is absolutely important to sustain efforts in the fight against the pandemic” – said Miron Tokarski, co-founder and president of Genomtec.


Our privacy policy